Objective: This exploration aims to dissect the therapeutic paradox presented by muscle augmentation strategies in Myasthenia Gravis (MG) and Parkinson’s Disease (PD), offering a comparative analysis of the pathophysiological and therapeutic implications of muscle mass enhancement in these conditions.

Background: Myasthenia Gravis, an autoimmune neuromuscular disorder, is marked by compromised acetylcholine receptor functionality, resulting in muscle weakness and fatigue. Conversely, Parkinson’s Disease, a neurodegenerative disorder, is characterized by dopaminergic neuron depletion, manifesting as involuntary movements and muscle rigidity. The differential impact of muscle strengthening in these diseases underscores a complex therapeutic dichotomy.

Method: This analysis integrates a review of current literature on the pathophysiology of MG and PD, focusing on the effects of muscle mass and strength variations. Additionally, it considers the pharmacological treatment nuances, including the implications of mycophenolate in MG and the psychiatric management of comorbid conditions with Effexor, Klonopin, and Buspar.

Results: In MG, enhancing muscle mass exacerbates symptoms by increasing acetylcholine demand and depleting available receptors, leading to intensified weakness. In contrast, PD patients benefit from increased muscle strength, which improves mobility, balance, and overall quality of life. The therapeutic regimen’s complexity is magnified by the psychiatric side effects of mycophenolate, necessitating a judicious approach to managing GAD and Depression in this cohort.

Conclusion: The therapeutic landscape of MG and PD reveals a nuanced paradox in muscle augmentation’s role. While MG management may caution against increased muscle workload, PD therapy often incorporates strength enhancement as a pivotal component. This dichotomy necessitates a personalized, multidisciplinary approach, emphasizing the integration of neuropharmacological treatment with physical and psychiatric interventions to tailor therapeutic strategies effectively to each patient’s unique clinical profile.

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/muscle-augmentation-paradox-contrasting-therapeutic-approaches-in-myasthenia-gravis-and-parkinsons-disease/